See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

First Infant Enrolled in Trial of Roflumilast Cream, 0.05% for Atopic Dermatitis in Infants

Summary by contemporarypediatrics.com
The phase 2 trial will be 4 weeks and evaluate investigational, once-daily roflumilast cream 0.05% in infants 3 months to less than 2 years of age.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

contemporarypediatrics.comcontemporarypediatrics.com

First infant enrolled in trial of roflumilast cream, 0.05% for atopic dermatitis in infants

The phase 2 trial will be 4 weeks and evaluate investigational, once-daily roflumilast cream 0.05% in infants 3 months to less than 2 years of age.

Read Full Article
Arcutis BiotherapeuticsArcutis Biotherapeutics

Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis - Arcutis Biotherapeutics

Open the article to view the coverage from Arcutis Biotherapeutics

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Arcutis Biotherapeutics broke the news in on Tuesday, June 10, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal